Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | SCD | O00767 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261276 | 0.88 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12686845 | 0.87 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14151235 | 0.81 | NPC1 (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2931584 | 0.80 | AKR1C3 (0.46) | AKR1C3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2929452 | 0.80 | AKR1C3 (0.71) | AKR1C3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2924726 | 0.80 | CSNK2A1 (0.60) | AKR1C3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15277719 | 0.79 | MAP4K4 (0.49) | NPC1RAB9ASMN1; SMN2TOP1DYRK1A | |
| SCHEMBL2932310 | 0.77 | TOP1 (0.52) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2932046 | 0.76 | AKR1C3 (0.47) | AKR1C3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15274893 | 0.76 | PTGER3 (0.42) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2992880-A1 | Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau (ES) | 2016-03-09 | — | — | EP | claimed |
| US-10888569-B1 | Methods and compositions for treating cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-01-12 | — | — | US | disclosed |
| US-9707239-B2 | Compounds that modulate oxidative stress | VTV THERAPEUTICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170189411-A9 | Compounds That Modulate Oxidative Stress | VTV THERAPEUTICS LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170056413-A1 | Compounds That Modulate Oxidative Stress | VTV THERAPEUTICS LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9447468-B2 | Compounds that modulate oxidative stress | VTV THERAPEUTICS LLC (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2992880-A1 | Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau (ES) | 2016-03-09 | — | — | EP | disclosed |
| US-20130253007-A1 | Compounds That Modulate Oxidative Stress | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189411-A9 | Compounds That Modulate Oxidative Stress | TXNRD2, GPX4, TXN2 | AKR1C3 338/4885PTP4A3 2259/4885NPC1 1064/4885 |
| US-20170056413-A1 | Compounds That Modulate Oxidative Stress | TXNRD2, GPX4, TXN2 | AKR1C3 338/4885PTP4A3 2259/4885NPC1 1064/4885 |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885PTP4A3 2539/4885NPC1 653/4885 |
| US-10888569-B1 | Methods and compositions for treating cancer | BACH1, BCOR, BCCIP | AKR1C3 2850/4885PTP4A3 3442/4885NPC1 1918/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885PTP4A3 2539/4885NPC1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.